Bicara Therapeutics Inc. earnings date
Want to see BCAX full AI Analyst Report?
Bicara Therapeutics Inc. (BCAX) Q3 2026 Earnings Report
BCAX Q3 2026 EPS Results
- Actual EPS
- -$1.04
- Consensus EPS
- -$0.82
- Beat/Miss
- Missed by -$0.22
- One Year Ago EPS
- -$0.67
BCAX Q3 2026 Revenue Results
- Actual Revenue
- $0
- Expected Revenue
- $0
- Beat/Miss
- Met expectations
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/09/2026
- Time
- Before Open
- Conference Call
- Monday, November 9, 2026
Bicara Therapeutics Inc.'s next earnings date is estimated for April 1, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was predominantly positive, driven by substantial pivotal-trial enrollment, plans for an interim overall survival analysis, encouraging and durable Phase Ib efficacy data, Breakthrough Therapy designation, commercial preparation, and a cash runway into the first half of 2029. The main negatives were sharply higher operating expenses, the absence of pivotal data to date, pending regulatory clarity, a competitive market, and the still-early, late-line status of the colorectal cancer program.
Bicara expects top line interim analysis from FORTIFI-HN01 in the middle of next year and plans to incorporate an interim overall survival analysis, although it has not guided to when that will occur; the study is around 650 patients and the company does not expect to need to upsize it. CRC data are planned for presentation in January, FORTIFI-FLEX data are anticipated prior to the first approval, and its overall design remains unchanged. The company anticipates that overall operating expenses through year-end will remain consistent with its most recent quarterly results, while approximately $442.3 million in cash, cash equivalents and marketable securities provides cash runway into the first half of 2029. Bicara continues to view timing as less than a year between itself and petosemtamab.
- Substantial Enrollment in FORTIFI-HN01The pivotal FORTIFI-HN01 study has achieved substantial enrollment sufficient to enable a top-line interim analysis, which the company continues to expect in the middle of next year. Bicara also confirmed plans for an interim overall survival analysis and said the approximately 650-patient, HPV-negative-only study does not need to be upsized.
- Strong Phase Ib Clinical ResultsAt the 1,500-milligram weekly dose with a median follow-up of 3 years, FICERA plus pembrolizumab achieved a confirmed objective response rate of 54% and a complete response rate of 25%. Eighty percent of responders had tumor shrinkage of 80% or more, responses occurred at a median of about 6 weeks, and median duration of response was nearly 22 months.
- Progression-Free and Overall Survival SignalsThe Phase Ib data showed median progression-free survival of 9.9 months, described as roughly 3x what has been reported for pembrolizumab alone, and median overall survival of just over 21 months. About 1 in 3 patients was alive at 3 years, which the company described as roughly double what real-world data would suggest for pembrolizumab alone in HPV-negative patients.
- Durability in Deep RespondersAcross all three Phase Ib dose cohorts—750 milligrams weekly, 1,500 milligrams weekly, and 2,000 milligrams every 2 weeks—patients with deep responses remained in response for a median of more than 2.5 years and went nearly 3 years without progression. Median overall survival had not yet been reached in that group.
- Biologic Rationale and Tumor Microenvironment FindingsFICERA was designed to inhibit both EGFR and TGF-beta and work synergistically with immunotherapy. Paired biopsies showed reduced TGF-beta signaling in the tumor and greater CD8 T-cell infiltration, findings the company believes support the observed depth and durability of response.
- Focus on an Underserved HPV-Negative PopulationBicara is enrolling only HPV-negative patients in FORTIFI-HN01, a population the company said represents roughly 80% to 90% of head and neck cancer cases globally and has the worst prognosis. The Phase Ib data set was also entirely HPV-negative, included many patients with locoregional disease and bulky tumors, and showed similar responses regardless of PD-L1 CPS.
- Breakthrough Therapy Designation and FDA EngagementFICERA has received Breakthrough Therapy designation specifically for HPV-negative head and neck cancer based on differentiated clinical data. Bicara said the designation facilitates ongoing, real-time interactions with the FDA.
- Advancement of Flexible Dosing and Commercial PreparationBicara advanced FORTIFI-FLEX to evaluate a less frequent dosing option requested by physicians, with data expected before the company's first approval. The company also said its commercial leadership team, with more than 50 collective new-product launches, is in place, while disease education, payer and access strategy, and data and analytics infrastructure are underway.
- Large Commercial OpportunityThe company estimates that roughly 50,000 patients across the U.S., EU5, and Japan are newly diagnosed each year with HPV-negative disease, including about 18,000 in the U.S. The global head and neck cancer market is projected to reach more than $5 billion by 2030.
- Early Signals in Colorectal CancerIn the Phase Ib expansion study in third-line MSS RAS/BRAF wild-type metastatic colorectal cancer, FICERA monotherapy and FICERA plus pembrolizumab are showing encouraging early safety and efficacy signals. Bicara plans to present the data at a relevant forum in January and is evaluating whether the efficacy and safety profile supports development in earlier lines.
- Extended Cash RunwayBicara ended the third quarter with approximately $442.3 million in cash, cash equivalents, and marketable securities, providing cash runway into the first half of 2029. The runway includes the pivotal study through final overall survival analysis, a planned regulatory filing, initial medical and commercial infrastructure, FORTIFI-FLEX, manufacturing, and general corporate purposes.
- Competitive Timing PositionBicara continues to expect less than a year between its potential approval and petosemtamab's approval, a timing relationship it views as important based on historical analogs. Management said it has not shifted its view of the expected timing relative to petosemtamab.
BCAX Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 01, 2027 | 2026 (Q4) | -1.04- | -0.93 | ― | ― |
| Nov 09, 2026 | 2026 (Q3) | -0.82-1.04 | -0.67 | -55.22% (-0.37) | |
| Aug 11, 2026 | 2026 (Q2) | -0.82-0.82 | -0.5 | -64.00% (-0.32) | |
| May 11, 2026 | 2026 (Q1) | -0.65-0.93 | -0.68 | -36.76% (-0.25) | |
| Mar 30, 2026 | 2025 (Q4) | -0.67-0.68 | -0.39 | -74.36% (-0.29) | |
| Nov 18, 2025 | 2025 (Q3) | -0.54-0.67 | -1.6 | 58.13% (+0.93) | |
| Aug 12, 2025 | 2025 (Q2) | -0.55-0.50 | -0.45 | -11.11% (-0.05) | |
| May 13, 2025 | 2025 (Q1) | -0.41-0.68 | ― | ― | |
| Mar 27, 2025 | 2024 (Q4) | -0.33-0.39 | ― | ― | |
| Nov 12, 2024 | 2024 (Q3) | -0.41-1.60 | -0.42 | -280.95% (-1.18) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


